Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Catalyst Health
So what: Walgreen nets a nice cash payment as it gets out of a competitive, administratively burdensome business that Catalyst happens to specialize in. If all goes well, the handoff will be completed by June.
Now what: And that's when the money should begin to roll in for Catalyst. The company's volume of prescriptions under management will more than double to 165 million, Reuters reports. Its membership rolls will also more than double, from 7 million to more than 18 million.
There's a lot of profitable growth to come as a result of this deal. Probably a lot more than the 19.5% a year analysts had been calling for before today's announcement.
Fool contributor Tim Beyers is a member of the Motley Fool Rule Breakers stock-picking team. He didn't own shares in any of the companies mentioned in this article at the time of publication. Check out Tim's portfolio holdings and Foolish writings, or connect with him on Twitter as @milehighfool. You can also get his insights delivered directly to your RSS reader. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool is also on Twitter as @TheMotleyFool. Its disclosure policy is at least 10% better than other disclosure policies.